Search

Displaying results 2601 - 2610 of 7604 in total
  1. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell growth and survival.[L50587]

    Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide
  3. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  4. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. … Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous

  5. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate has been discontinued in the US market.

  6. Drug

    Cyclophosphamide

    go.drugbank.com/drugs/DB00531
    ApprovedInvestigational

    Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.

    Synonyms: N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
  7. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). … The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for

  8. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    It is not yet approved for use in the U.S., E.U., or Canada. … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.

  9. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine … N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.

    Synonyms: N-Methyl nicotineamide, 3-(N-Methylcarbamoyl)pyridine
  10. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

    Synonyms: N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine